Recent Updates — ATHE
Alterity Therapeutics raised approximately A$5.5 million through the exercise of listed options and received an A$3.98 million R&D tax refund, bringing its cash balance to A$41.3 million at September 30, 2026. The company confirmed alignment with the FDA on the Phase 3 trial design for ATH434 in Multiple System Atrophy (MSA) and began operational start-up activities, including vendor selection and site identification. Additionally, the USPTO granted a new composition of matter patent for ATH434 extending protection to 2045. Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases.
David Stamler, Chief Executive Officer of Alterity Therapeutics, will participate in a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday, October 22, 2026, at 2:30 p.m. ET. The company is preparing to initiate a Phase 3 pivotal trial for its lead asset, ATH434, in Multiple System Atrophy (MSA), following positive data from earlier clinical trials. Alterity Therapeutics Limited operates as a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases.
Alterity Therapeutics announced that CEO David Stamler will deliver a corporate presentation and host investor roundtables at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026. The company is a clinical-stage biotechnology firm focused on developing disease-modifying therapies for neurodegenerative diseases, specifically Multiple System Atrophy (MSA). Its lead asset, ATH434, has shown efficacy in Phase 2 trials, and the company is preparing to initiate a pivotal Phase 3 trial.
Alterity Therapeutics presented new analyses from its randomized, double-blind, placebo-controlled ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. After adjusting for baseline disease severity using cerebrospinal fluid neurofilament light chain (CSF NfL), ATH434 50 mg significantly slowed functional decline on the 11-item UMSARS Part I by approximately 52% versus placebo at Week 52, with a -4.64-point difference compared to placebo. The analysis also demonstrated that higher baseline CSF NfL predicts greater clinical decline, supporting its use as a severity covariate in future trials. Brain iron MRI imaging results were consistent with the drug's mechanism of action as an iron chaperone, although the primary endpoint for substantia nigra iron change was not met. Alterity Therapeutics is a biotechnology company developing disease-modifying treatments for neurodegenerative diseases.